MedTrace Logo

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

NCT03030105 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2018-10-16

No results posted yet for this study

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, 6-period crossover study to evaluate the effects of BPN14770 10 mg and 50 mg in reversing scopolamine-induced cognitive impairment in healthy volunteers. A positive control, donepezil 10 mg, will be included, and additivity of BPN14770 50 mg to donepezil 10 mg in reversing scopolamine effects will also be evaluated.

Conditions

  • Alzheimer Disease

Interventions

DRUG

BPN14770

investigational drug

DRUG

BPN14770 placebo

placebo

DRUG

Donepezil

comparator

DRUG

Donepezil placebo

placebo

DRUG

Scopolamine 0.6 MG/ML

cognition impairment

DRUG

Scopolamine placebo

placebo

Sponsors & Collaborators

  • Tetra Discovery Partners

    lead INDUSTRY

Principal Investigators

  • Cassandra Key, MD · ICON Early Phase Services, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2017-05-31
Completion
2017-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03030105 on ClinicalTrials.gov